Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Reviva Labs For Collagen-Building, Anti-Inflammatory Claims

This article was originally published in The Rose Sheet

Executive Summary

FDA cites Reviva for unapproved drug claims on eight of its products marketed as cosmetics. Included among targeted claims are familiar statements about collagen production, inflammation reduction and other benefits the agency views as structure/function effects. A number of the claims onceivably could be allowed under the revised "cosmetic" definition proposed by the Cosmetic Modernization Amendments of 2015.

Advertisement

Related Content

MGC Navigates Regulatory Uncertainty With Cannabis Skin Care
What Comes First In Consumer Sector: FDA Excessive Claims Finding Or Facility Inspection?
What Comes First In Consumer Sector: FDA Excessive Claims Finding Or Facility Inspection?
What Comes First In FDA Land, Excessive Claims Finding Or Facility Inspection?
PCPC: Cosmetic Legislation A Long Shot In 2016, But Objectives Are Clear
New Litigation Risks Possible From Pending Allergan V. Athena Case
Aligning U.S. With EU Cosmetic Definition Could Enable Claims, Reduce FDA Warnings
Regulatory Roulette: Playing In Today’s Skin-Care Market A Gamble
FDA Warning To L’Oreal Creates Uncertainty For Anti-Redness, Dark Spot Treatments
Aggressive Claims, FDA Warnings Make Beauty A Bull’s Eye For Litigation

Topics

Advertisement
UsernamePublicRestriction

Register

RS019920

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel